Feel free to reach out to us.
16 Mar, 2026
Blood tests used to detect cancer measure proteins, abnormal cell patterns, or genetic fragments associated with cancer activity. They fall into three broad categories: tumor marker panels such as PSA, CEA, CA-125, and AFP; routine counts like the complete blood count (CBC); and liquid biopsy. Doctors order these to investigate unexplained symptoms, assess risk, or monitor treatment. A blood test cannot confirm a diagnosis alone; results are interpreted alongside examination, imaging, and biopsy.
Blood tests can identify elevated proteins, abnormal cell counts, or genetic fragments that may suggest cancer activity. They cannot locate a tumor or confirm a diagnosis.
An abnormal result means something warrants closer investigation, not that cancer is confirmed. Infections, benign growths, and inflammatory conditions produce the same findings. Any concerning result prompts further evaluation.
Three categories of blood tests are used in oncology, each measuring something different for a distinct diagnostic purpose.
| Test Type | Examples | What It Detects | Primary Use |
|---|---|---|---|
| Tumor Marker Tests | PSA, CEA, CA-125, AFP | Cancer-associated proteins | Evaluation and monitoring |
| Routine Blood Tests | CBC, blood chemistry | Abnormal cell counts, organ function | Initial assessment and monitoring |
| Liquid Biopsy | ctDNA, CTC testing | Cancer-related genetic material | Monitoring and treatment decisions |
Tumor markers are proteins or substances produced by cancer cells or by the body in response to cancer. A raised marker is not exclusive to cancer. Most are more useful for monitoring a known diagnosis than for detecting cancer broadly.
PSA is produced by the prostate gland. Raised levels can prompt investigation for prostate cancer, but elevated PSA also results from benign prostate enlargement, inflammation, or infection. The test supports initial assessment and ongoing monitoring.
CEA is primarily associated with colorectal cancer, though elevated levels can appear in other cancers and non-cancerous conditions. Doctors track it over time because a rising CEA may suggest disease activity.
CA-125 is associated with ovarian cancer and is used most often to monitor patients already diagnosed. Elevated CA-125 can appear in endometriosis or pelvic inflammatory disease, limiting its standalone reliability.
Quick note: CA-125 is better suited for tracking how a known ovarian cancer responds to treatment than for screening women without symptoms.
AFP is associated with liver cancer and certain testicular cancers. Raised levels support initial evaluation and assess treatment response. It's worth noting that AFP levels can also rise in conditions like hepatitis and cirrhosis, so an elevated result doesn't automatically mean cancer.
Once collected, the sample goes to a pathology laboratory. Routine results are typically available within five to seven working days (NHS). Molecular or genetic testing may extend this to two weeks. The treating physician reviews findings at a follow-up appointment and explains what they mean for the next stage of care.
A CBC looks at your red blood cells, white blood cells, and platelets. If your white blood cell count is off, or if you have anemia that doesn't have an obvious explanation, it could be a sign that something like leukemia or lymphoma needs to be ruled out.
Quick note: A CBC can help detect certain blood cancers but cannot detect solid organ cancers such as lung or colorectal cancer.
The same patterns can result from infections, nutritional deficiencies, and many other causes. Any abnormal CBC requires follow-up testing before a diagnosis is considered.
Liquid biopsy analyzes a blood sample for circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) shed by tumors into the bloodstream. Unlike tumor marker tests, it examines genetic fragments associated with tumor activity.
At present, liquid biopsy is most commonly used to monitor treatment response, detect mutations guiding therapy decisions, and identify early recurrence. The NCI notes that multi-cancer detection tests examining ctDNA are under active study, but clinical application varies by setting.
No blood test available today can confirm a cancer diagnosis alone. A tissue biopsy is required in almost all cases before any definitive conclusion is reached.
Elevated tumor markers can result from benign conditions, and some cancers produce no detectable marker changes. A PubMed Central (NIH) review notes that tumor markers have limitations in specificity and sensitivity and must be used alongside imaging and pathological examination. False positives cause anxiety.
In Summary: Blood tests open the door to investigation. They do not close the loop on diagnosis. That requires tissue confirmation in nearly every case.
Blood tests for cancer serve two different purposes. Screening tests people without symptoms for early abnormalities. Only a limited number, such as PSA in select patient groups, are used this way, within a broader clinical assessment. Monitoring involves regular testing in patients already diagnosed or treated to track response or detect recurrence.
A blood test may be ordered for unexplained weight loss, persistent fatigue, or findings in a consultation. Known risk factors and follow-up after treatment are other common reasons. Self-ordering without clinical guidance is not recommended, as results require full knowledge of a patient's history.
Blood tests are a meaningful part of cancer evaluation, working best as one component of a broader diagnostic process. Each type offers specific information alongside limitations equally important to understand.
At HCG's Comprehensive Cancer Centers, each patient's diagnostic journey is approached with evidence-based planning and coordinated, multidisciplinary review. Tests are recommended within a clinical context, and results are never considered in isolation.
Speaking with a specialist is the most reliable next step if you are preparing for or interpreting a cancer blood test result.
- National Cancer Institute (cancer.gov) | Tumor Markers | https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet
- Cancer Research UK (cancerresearchuk.org) | Blood Tests | https://www.cancerresearchuk.org/about-cancer/tests-and-scans/blood-tests
- MedlinePlus / NIH (medlineplus.gov) | Tumor Marker Tests | https://medlineplus.gov/lab-tests/tumor-marker-tests/
- MedlinePlus / NIH (medlineplus.gov) | CA-125 Blood Test | https://medlineplus.gov/lab-tests/ca-125-blood-test-ovarian-cancer/
- MedlinePlus / NIH (medlineplus.gov) | AFP Tumor Marker Test | https://medlineplus.gov/lab-tests/alpha-fetoprotein-afp-tumor-marker-test/
- Cleveland Clinic (my.clevelandclinic.org) | Blood Tests for Cancer | https://my.clevelandclinic.org/health/diagnostics/22338-blood-tests-for-cancer
- PubMed Central / NIH (pmc.ncbi.nlm.nih.gov) | Tumor Markers in Clinical Practice | https://pmc.ncbi.nlm.nih.gov/articles/PMC5586699/
- PubMed Central / NIH (pmc.ncbi.nlm.nih.gov) | Laboratory Evaluation of Tumor Biomarkers | https://www.ncbi.nlm.nih.gov/books/NBK597378/